EMS-CHEMIE HOLDING AG EMSN.SW
Composite 62/100; the shares have moved about 20% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 22/100 — a strong mark against it.
Balance-sheet strength ranks 92/100 — a strong point in its favour. Momentum ranks 81/100 — a strong point in its favour. Quality ranks 74/100 — a moderate point in its favour.
Valuation ranks 22/100 — a strong mark against it. Growth ranks 37/100 — a moderate mark against it.
What the company does EMS-CHEMIE HOLDING AG (EMSN.SW) is a Swiss specialty chemicals and high‑performance polymers group serving automotive, electronics, textiles, coatings and packaging with products such as polyamide granulate, adhesives, fibers and powder coatings.
Key financials The company posts ROE 25% and ROCE 56%, with gross, operating and net margins of 49%, 29% and 24%. Revenue is down 5% YoY while EPS is up 2%. Debt/equity is 0.02 and interest coverage is 326x, underpinning balance-sheet strength.
Stock health Momentum is strong: +21% in 3m, +34% in 6m and +26% in 12m; RSI(14) is 82, indicating overbought conditions. Sideravia scores Quality 77 and Strength 96, but Valuation is only 19.
Price vs fair value The stock trades at a PREMIUM of 60.60% versus our fair-value estimate of 318.32 and a PREMIUM of 9.96% versus the 12-month analyst target of 728.00. - Trading at a 40x P/E vs 25x forward multiple (Valuation 18.6) - PEG of 7.69 vs sector median around 1.5 (Valuation 18.6) - RSI at 82 signals overbought momentum (Momentum 75.1) - Analysts (n=7) still see 10% upside to 728 (PREMIUM 9.96%)
Looking forward Forward P/E of 25x and FCF yield of 2% imply fair value closer to 728, but current price implies a 61% premium to intrinsic value. Growth remains subdued (-5% revenue), keeping multiples rich despite high profitability.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.